Rhonda B Kean's research while affiliated with Thomas Jefferson University and other places

... This receptor regulates key processes, including transformation, cell survival, and the inhibition of apoptosis [29]. Malignant cells were intraoperatively harvested from patients with GBM, treated with ASOs, and re-implanted into the abdomen within a biodiffusion chamber [28,61]. Western blot analysis confirmed a decreased IGF-1 expression after ASO treatment. ...

... Further, 38% of dogs in vaccinated wards with inadequate RFFIT titer (<0.5 IU/mL) showed adequate levels of IFN-γ (≥3 ± 1 pg/mL), and surprisingly, 100% of the dogs from wards where MDV was not implemented and also had inadequate RFFIT titer (<0.5 IU/mL) showed adequate levels of IFN-γ. This may be attributed to the previous vaccinations undertaken as part of the ABC-ARV program and the T-cell memory [30][31][32]. ...

... This combination therapy of RT and PD-1/PD-L1 inhibitor improved the longterm survival in preclinical studies and mouse models of melanoma, colorectal cancer, breast cancer, and NSCLC [175][176][177], while also preventing tumor recurrence. It has also shown good promise in some clinical trials: 1. RT increases the effectiveness of PD-L1 inhibition, and 2. In combination with PD-L1 inhibitors, RT increases the patients' survival [178,179]. ...

... The receptors for VIP occurs in numerous tumor cells including thyroid, breast, lung, liver, pancreas, intestinal epithelial cells, colon, bladder, prostate, uterus, and neuroendocrine tumors [178,179]. -colorectal -gamma camera -useful for early tumor SPECT staging due to appropriate tumor accumulation, high stability, low liver accumulation, and high kidney excretion - 68 Ga -DOTA(tBu)3 -4-amino piperidin-1-yl-acetic acid -Lys 8 -Lys 9 -Pro 10 -Tyr 11 -Ile 12 -Leu 13 -preclinical in vitro, in vivo -breast -PET/CT -low in vivo stability, but greater VPAC-affinity and tumor [189] delineation only for NODAGA-conjugate - 64 Cu -N2S2 chelator -x -TP3805 -preclinical in vitro, in vivo -brain -microPET/CT -more specific brain tumor delineation than [ 18 F]FDG, further investigation for clinical translation warranted [190] ...

... Promising results were also obtained with a treatment based on autologous glioma cells treated ex vivo with an antisense oligodeoxynucleotide targeting the IGF-IR (IGF-1R/AS ODN) and re-implanted in patients. Seventeen out of 33 individuals enrolled in a phase Ib trial (NCT02507583) remained progression-free and 12 of them are still alive, demonstrating that an autologous cell vaccine may significantly prolong progression free survival (PFS) and OS compared to standard of care (107). ...

... In two prospective trials ( Segal et al., 2016;Lin et al., 2017a) only mild drug-related toxicities was reported in patients affected by meta- static colo-rectal cancer and renal cell carcinoma, both treated with Pembrolizumab and ablative or palliative RT. In a phase II trial ( Ho et al., 2017) including 9 patients with triple-negative metastatic breast cancer treated with RT and Pembrolizumab, only mild toxicities were preliminarily reported. ...

... Moreover, cellular immune reaction occurs only when the virus moves out from the CNS and can be immunologically recognized. 49 ...

... Accumulating evidence suggests that integrins found in EVs may promote a proinvasive tumor microenvironment, aiding cells in migration [40,41], immune system remodeling [42], and adhesion and uptake [43]. Exosomal integrins may direct organotropic metastasis after uptake by distant cells [44,45], or even create a migratory leading edge following chemotaxis [40]. ...

... Moreover, the intensity of the Th1 response to the inactivated rCVS11-MAB2560 virus was significantly increased compared to that in the inactivated rCVS11 group (Fig 7), indicating that MAB2560 protein expressed by rCVS11-MAB2560 played an important role in inducing host immune response as an effective Th1 polarizing adjuvant [32]. A strong Th 1 response can provide better protection against RABV infection because the Th1 immune response is a potent inducer of anti-viral effector functions [46,47]. Meanwhile, compared to the inactivated rCVS11 group, the group exposed to the recombinant virus rCVS11-MAB2560 showed that more effector T cells had been stimulated to differentiate into CD4 + memory T cells, which helps the host acquire the ability to mount a secondary response quickly upon subsequent viral antigen exposure (Fig 8). ...

... A neutralizing antibody is effective in neutralizing an extracellular virus, but is less likely to clear an intracellular virus [63]. Lebrun et al. have reported that a strong Th2 response in mice did not guarantee survival when the rabies virus reached central nervous tissues [64]. The delay in stopping the virus from spreading from the periphery to the central nervous system will irretrievably lead to the development of rabies. ...